• Evonik entered a partnership with evitria to market a ready-to-use CHO-based transient protein expression kit for early-stage biologics R&D.
• The eviCHO Expression Kit targets faster, more reliable, scalable protein production, aiming to shorten early biologics development timelines.
• Collaboration expands Evonik’s Advance Precision Biosolutions offering, strengthening its position in the biopharma value chain.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evonik Industries AG published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.